
Roslyn A Kemp

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1960535/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tumor-Specific Tc1, But Not Tc2, Cells Deliver Protective Antitumor Immunity. Journal of Immunology, 2001, 167, 6497-6502.	0.8	126
2	Gene Microarrays Reveal Extensive Differential Gene Expression in Both CD4+ and CD8+ Type 1 and Type 2 T Cells. Journal of Immunology, 2001, 167, 3057-3063.	0.8	123
3	Regulatory Tâ€cell heterogeneity and the cancer immune response. Clinical and Translational Immunology, 2017, 6, e154.	3.8	96
4	Tertiary lymphoid structures in cancer – considerations for patient prognosis. Cellular and Molecular Immunology, 2020, 17, 570-575.	10.5	94
5	Repeated stimulation of CD4 effector T cells can limit their protective function. Journal of Experimental Medicine, 2005, 201, 1101-1112.	8.5	88
6	Activation of the NLRP3 inflammasome is not a feature of all particulate vaccine adjuvants. Immunology and Cell Biology, 2014, 92, 535-542.	2.3	64
7	Dendritic cell elimination as an assay of cytotoxic T lymphocyte activity in vivo. Journal of Immunological Methods, 2000, 246, 109-117.	1.4	50
8	Chitosan hydrogels containing liposomes and cubosomes as particulate sustained release vaccine delivery systems. Journal of Liposome Research, 2012, 22, 193-204.	3.3	48
9	Intestinal Organoids as a Tool for Inflammatory Bowel Disease Research. Frontiers in Medicine, 2019, 6, 334.	2.6	44
10	Cutting Edge: Regulation of CD8+T Cell Effector Population Size. Journal of Immunology, 2004, 173, 2923-2927.	0.8	38
11	Gut macrophage phenotype is dependent on the tumor microenvironment in colorectal cancer. Clinical and Translational Immunology, 2016, 5, e76.	3.8	34
12	CD8+ T cells responding to influenza infection reach and persist at higher numbers than CD4+ T cells independently of precursor frequency. Clinical Immunology, 2004, 113, 89-100.	3.2	33
13	Inflammatory and regulatory T cells contribute to a unique immune microenvironment in tumor tissue of colorectal cancer patients. International Journal of Cancer, 2013, 132, 1842-1850.	5.1	33
14	Chitosan hydrogel vaccine generates protective CD8 T cell memory against mouse melanoma. Immunology and Cell Biology, 2015, 93, 634-640.	2.3	30
15	The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumorâ€infiltrating TÂcells. Immunology and Cell Biology, 2019, 97, 152-164.	2.3	29
16	The phenotype of type 1 and type 2 CD8+ T cells activated in vitro is affected by culture conditions and correlates with effector activity. Immunology, 2005, 115, 315-324.	4.4	27
17	Immune cell interplay in colorectal cancer prognosis. World Journal of Gastrointestinal Oncology, 2015, 7, 221.	2.0	27
18	Survival of Listeria monocytogenes in sea water and effect of exposure on thermal resistance. Journal of Applied Microbiology, 1998, 85, 545-553.	3.1	24

ROSLYN A KEMP

#	Article	IF	CITATIONS
19	Thermal Death Times of Hafnia alveiCells in a Model Suspension and in Artificially Contaminated Hot-Smoked Kahawai (Arripis trutta). Journal of Food Protection, 1998, 61, 1047-1051.	1.7	24
20	Inclusion of BLIMP-1+ effector regulatory T cells improves the Immunoscore in a cohort of New Zealand colorectal cancer patients: a pilot study. Cancer Immunology, Immunotherapy, 2017, 66, 515-522.	4.2	23
21	Immunomodulators in Inflammatory Bowel Disease: An Emerging Role for Biologic Agents. BioDrugs, 2013, 27, 585-590.	4.6	21
22	Chitosan gel vaccine protects against tumour growth in an intracaecal mouse model of cancer by modulating systemic immune responses. BMC Immunology, 2016, 17, 39.	2.2	21
23	Urinary Soluble HLA-DR Is a Potential Biomarker for Acute Renal Transplant Rejection. Transplantation, 2010, 89, 1071-1078.	1.0	20
24	High-Dimensional Mass Cytometric Analysis Reveals an Increase in Effector Regulatory T Cells as a Distinguishing Feature of Colorectal Tumors. Journal of Immunology, 2019, 202, 1871-1884.	0.8	19
25	Lipid-encapsulated oral therapeutic peptide vaccines reduce tumour growth in an orthotopic mouse model of colorectal cancer. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 152, 183-192.	4.3	17
26	Functional impairment of infiltrating T cells in human colorectal cancer. Oncolmmunology, 2016, 5, e1234573.	4.6	16
27	Multiparametric analysis of colorectal cancer immune responses. World Journal of Gastroenterology, 2018, 24, 2995-3005.	3.3	16
28	Bacteria biohybrid oral vaccines for colorectal cancer treatment reduce tumor growth and increase immune infiltration. Vaccine, 2021, 39, 5589-5599.	3.8	13
29	Making the most of highâ€dimensional cytometry data. Immunology and Cell Biology, 2021, 99, 680-696.	2.3	12
30	Styrene maleic acid-encapsulated paclitaxel micelles: antitumor activity and toxicity studies following oral administration in a murine orthotopic colon cancer model. International Journal of Nanomedicine, 2016, Volume 11, 3979-3991.	6.7	11
31	Improved Antitumor Activity of a Therapeutic Melanoma Vaccine through the Use of the Dual COX-2/5-LO Inhibitor Licofelone. Frontiers in Immunology, 2016, 7, 537.	4.8	9
32	A defined serum-free medium useful for monitoring anti-melanoma responses induced by dendritic cell immunotherapy. Journal of Immunological Methods, 2010, 352, 178-181.	1.4	8
33	Evidence of STAT5â€dependent and â€independent routes to CD8 memory formation and a preferential role for ILâ€7 over ILâ€15 in STAT5 activation. Immunology and Cell Biology, 2010, 88, 213-219.	2.3	8
34	Prognostic roles for IL â€2â€producing and CD 69 + T cell subsets in colorectal cancer patients. International Journal of Cancer, 2018, 143, 2008-2016.	5.1	8
35	Human Systemic Immune Response to Ingestion of the Oral Probiotic Streptococcus salivarius BLIS K12. Probiotics and Antimicrobial Proteins, 2021, 13, 1521-1529.	3.9	8
36	Distinct immune signatures in the colon of Crohn's disease and ankylosing spondylitis patients in the absence of inflammation. Immunology and Cell Biology, 2016, 94, 421-429.	2.3	7

ROSLYN A KEMP

#	Article	IF	CITATIONS
37	Normal levels of immunocompetence in possums (Trichosurus vulpecula) exposed to different laboratory housing conditions post capture. Immunology and Cell Biology, 2004, 82, 253-256.	2.3	4
38	T cell subpopulations in lymph nodes may not be predictive of patient outcome in colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2011, 30, 78.	8.6	4
39	Brick plots: an intuitive platform for visualizing multiparametric immunophenotyped cell clusters. BMC Bioinformatics, 2020, 21, 145.	2.6	4
40	Oestrogen deprivation induces chemokine production and immune cell recruitment in in vitro and in vivo models of oestrogen receptor-positive breast cancer. Breast Cancer Research, 2021, 23, 95.	5.0	3
41	Computational Analysis of High-Dimensional Mass Cytometry Data from Clinical Tissue Samples. Methods in Molecular Biology, 2019, 1989, 295-307.	0.9	2
42	Extensive variability in the composition of immune infiltrate in different mouse models of cancer. Laboratory Animal Research, 2020, 36, 43.	2.5	2
43	Probiotics and health: understanding probiotic trials. New Zealand Medical Journal, 2019, 132, 90-96.	0.5	2
44	Parapoxvirus Interleukin-10 Homologues Vary in Their Receptor Binding, Anti-Inflammatory, and Stimulatory Activities. Pathogens, 2022, 11, 507.	2.8	2
45	Assessment of source material for human intestinal organoid culture for research and clinical use. BMC Research Notes, 2022, 15, 35.	1.4	1
46	Planned withdrawal of dexamethasone after pomalidomide low dose dexamethasone induction for lenalidomide refractory multiple myeloma (ALLG MM14). Haematologica, 2021, , .	3.5	0
47	Identification of Novel Immune Cell Populations in Lenalidomide Refractory Relapsed Multiple Myeloma Patients Treated with Pomalidomide and Low Dose Dexamethasone. Blood, 2019, 134, 3186-3186.	1.4	0
48	Cancer Care at a Crossroads: time to make a choice. New Zealand Medical Journal, 2019, 132, 6-11.	0.5	0